RegulatoryApr 8, 2026, 06:06 AM
Coeptis Therapeutics Secures Nasdaq Global Market Listing Approval for Post-Merger Entity ZSQR, Satisfying Key Merger Condition
AI Summary
Coeptis Therapeutics Holdings, Inc. announced that Nasdaq has approved the listing of the post-merger company's common stock on the Nasdaq Global Market under the ticker symbol "ZSQR". This approval is contingent upon customary conditions and the successful closing of the proposed merger between Coeptis and Z Squared Inc. The company highlighted that this milestone satisfies a key closing condition for the pending merger, signaling progress towards the transaction's completion. The move from the Nasdaq Capital Market to the Nasdaq Global Market for the combined entity could enhance visibility and liquidity for investors.
Key Highlights
- On April 7, 2026, Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced Nasdaq approval for the listing of the post-merger company's common stock.
- The post-merger entity's common stock will trade on the Nasdaq Global Market under the new ticker symbol "ZSQR".
- The approval is subject to customary conditions and the closing of the proposed merger with Z Squared Inc.
- This Nasdaq listing approval marks the satisfaction of a key closing condition for the pending merger between Coeptis and Z Squared Inc.
- Coeptis's current common stock and warrants (COEPW) are listed on the Nasdaq Capital Market.